In May 2009, the US FDA granted accelerated approval to a monoclonal antibody against vascular endothelial growth factor A (VEGF)—an important molecule promoting endothelial cell proliferation, new vessel formation, and subsequent rapid tumor growth [22] in recurrent GBM patients. Here, VEGFA is linked to glioblastoma.